Global /South Korea /Healthcare /Drug Manufacturers - General /009300

Sam-A Pharm. Co., Ltd.

009300

• KRX: 009300 • Delayed

16,370KRW 0.1%

10.73 USD

As of 13 June 2026, Sam-A Pharm. Co., Ltd. has a market cap of $65.7M USD, ranking #28572 globally and #1530 in South Korea. It ranks #2588 in the Healthcare sector, and #922 in the Drug Manufacturers - General industry.

Global Rank

28572

Country Rank

1530

Sector Rank

2588

Industry Rank

922

Key Stats

Market Cap

$65.7MUSD

99.91B KRW

Enterprise Value

$6.04MUSD

9.21B KRW

Revenue (TTM)

$51.16MUSD

77.8B KRW

EBITDA (TTM)

$10.34MUSD

15.79B KRW

Net Income (TTM)

$8.51MUSD

12.94B KRW

EBITDA Margin

20%

Profit Margin

17%

PE Ratio

7.7

PS Ratio

1.3

PB Ratio

0.4

EV/EBITDA

0.6

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Heo Jun open_in_new

Employees

300

Founded

1945

Website

samapharm.co.kr open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.1%	1.1%	2.7%	3.2%	-2.8%	4.2%	-3.4%	2.4%	2.3%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	009300 삼아제약(주) ISIN: KR7009300005 Shares Out.: Shares Outstanding: 6.103M¹ Shares Float: 1.841M² TV: TradingView: KRX: 009300 SA: Stock Analysis: KRX: 009300 YF: Yahoo Finance: 009300.KS GF: Google Finance: KRX: 009300 BA: Barron's: 009300 MS: Morningstar: XKRX: 009300	16,370 KRW	TV: TradingView: KRX: 009300 SA: Stock Analysis: KRX: 009300 YF: Yahoo Finance: 009300.KS GF: Google Finance: KRX: 009300 BA: Barron's: 009300 MS: Morningstar: XKRX: 009300

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Sam-A Pharm. Co., Ltd.

Sam-A Pharm. Co., Ltd operates as a pharmaceutical company in South Korea. The company offers a range of pharmaceutical products in the areas of respiratory, antibiotics, anti-virals, anti-histamines, anti-fungals, dermatology, pain/inflammation, gastrointestinal, cardiovascular, metabolism, urological, and steroids, as well as psychotropic agents; and OTC products in the areas of respiratory, ant-analgesics, gastro-intestinal, topical, oral, and anti-histamines. It provides NOMA MEGAFFECT for stress relief, eye care, memory and blood lipid concentration enhancement, endurance enhancement, and the supply of vitamins and minerals; and NOMA-F gummy, NOMA CHEWABLE tablet, and NOMA GOLD chewable tablet for growth promotion, enhancement of nutritional deficiency, and supply of vitamins. The company was founded in 1945 and is based in Seoul, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Epis Holdings Co., Ltd. KRX: 0126Z0	$9.15B 13.91T KRW 14K%	-	South Korea
Sam Chun Dang Pharm. Co., Ltd. KRX: 000250	$6.77B 10.3T KRW 10K%	1958.1	South Korea
SK Biopharmaceuticals Co., Ltd. KRX: 326030	$5.24B 7.97T KRW 8K%	29.9	South Korea
ABL Bio Inc. KRX: 298380	$4.96B 7.55T KRW 7K%	-	South Korea
Yuhan Corp. KRX: 000100	$4.55B 6.92T KRW 7K%	35.9	South Korea
LigaChem Biosciences Inc. KRX: 141080	$4.44B 6.76T KRW 7K%	-	South Korea

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 1M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 833K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 549K%	97.4	United States
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 489K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 440K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 418K%	20.5	Switzerland

chevron_leftBack